Abstract
Baicalin, the main flavonoid component extracted from Scutellaria roots, has a variety of biological activities and is therefore used in the treatment of many kinds of diseases. However, whether baicalin affects the normal development of tissues and organs is still unclear. Here, using a mouse mammary gland model, we investigated the effects of baicalin on the expansion of mammary stem cells (MaSCs) and mammary development, as well as breast cancer progression. Interestingly, we found that baicalin administration significantly accelerates duct elongation at puberty, and promotes alveolar development and facilitates milk secretion during pregnancy. Furthermore, self-renewal of MaSCs was significantly promoted in the presence of baicalin. Moreover, in a tumor xenograft model, baicalin promoted tumor growth of the MDA-MB-231 cell line, but suppressed tumor growth of the ZR-751 cell line. Mechanistically, baicalin can induce expression of the protein C receptor, while inhibiting the expression of the estrogen receptor. Transcriptome analysis revealed that baicalin is involved in signaling pathways related to mammary gland development, immune response, and cell cycle control. Taken together, our results from comprehensive investigation of the biological activity of baicalin provide a theoretical basis for its rational clinical application.
Introduction
Mammary gland development is a complex physiological process primarily driven by steroid hormones like estrogen and progesterone. While Baicalin—a flavonoid derived from the root of Scutellaria baicalensis—is a staple of Traditional Chinese Medicine known for its anti-inflammatory and anti-cancer properties, its impact on normal tissue development remained largely unexplored. This study investigates whether Baicalin can mimic steroid hormone activities to regulate mammary gland growth and stem cell dynamics.
Methods
The researchers utilized a comprehensive experimental framework:
- In Vivo Models: Wild-type C57BL/6 mice were used to study pubertal and gestational development. Ovariectomized (OVX) mice were employed to assess Baicalin's ability to compensate for the loss of endogenous hormones.
- 3D Organoid Cultures: Primary mammary cells were cultured in Matrigel to evaluate colony formation and stem cell self-renewal.
- Cancer Xenografts: Nude mice were injected with MDA-MB-231 (Triple-Negative Breast Cancer) or ZR-75-1 (ER+ subtype) cells.
- Molecular Analysis: RNA-seq provided transcriptomic insights, while FACS and Luciferase assays characterized cell populations and gene regulation.
Key Results
Accelerated Pubertal Development
Baicalin treatment significantly accelerated mammary ductal elongation during puberty. In 5-week and 6-week-old mice, the distance from the nipple to the lymph node (LN) was significantly greater in the Baicalin-treated group compared to the vehicle control. By 9 weeks, both groups reached similar developmental stages, indicating that Baicalin primarily accelerates the early phases of pubertal growth.
Enhanced Alveolar Development During Pregnancy
The study also found that Baicalin promotes mammary gland maturation during pregnancy. Mice treated with Baicalin showed a marked increase in the number of alveolar buds at various stages of pregnancy (P5.5d, P10.5d, and P15.5d). This enhanced development suggests that Baicalin facilitates earlier milk secretion and more robust tissue expansion.
Stem Cell Expansion and Molecular Mechanism
Transcriptome analysis revealed that Baicalin acts as a steroid mimic, with a 40% overlap in gene regulation compared to estrogen and progesterone treatment. Mechanistically, Baicalin up-regulates the Protein C receptor (Procr), a marker for multipotent mammary stem cells (MaSCs), while down-regulating the Estrogen Receptor (ER). This shift promotes MaSC self-renewal, with transplantation assays showing a nearly four-fold increase in the repopulating frequency of Baicalin-treated cells.
Subtype-Specific Effects on Breast Cancer
The study highlights a critical "double-edged sword" effect in oncology. By inhibiting the estrogen receptor, Baicalin suppresses the growth of ER+ tumors (ZR-75-1). Conversely, by activating Procr and Wnt-related pathways, it significantly promotes the growth of Triple-Negative Breast Cancer (TNBC) tumors (MDA-MB-231), nearly doubling tumor weight in xenograft models.
Conclusion
Baicalin is a potent bio-mimic of steroid hormones that accelerates mammary development and expands the stem cell pool. However, its subtype-specific impact on breast cancer—suppressing ER+ tumors while fueling TNBC—underscores the necessity for precision in its clinical application. Future work is needed to identify the direct binding receptors of Baicalin and validate these findings in human clinical settings.
Summary updated